Pharmacotherapy of regional melanoma therapy

James Padsis, Ryan Turley, Douglas Tyler

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Importance of the field: In-transit melanoma metastases develop within regional dermal and subdermal lymphatics before reaching the regional lymph nodes. The prognosis is poor and comparable to multiple nodal metastases. Isolated limb infusion (ILI) or perfusion (ILP) are effective treatments for unresectable, in-transit melanoma, with response rates reaching 95%. Although ILI and ILP are more effective than systemic therapy, most patients will recur, thus highlighting the need for newer strategies to improve durable response rates. Areas covered in this review: We review historical and current literature from 1958 to 2009 regarding regional therapy for melanoma, with focus on the ILI and ILP techniques, pharmacokinetics and resistance mechanisms of melphalan. Alternative therapies, adjunct strategies and new targeted therapies aimed at improving response rates and long-term remission are also discussed. What the reader will gain: The reader will gain a comprehensive review on regional pharmacotherapy for melanoma, including alternative therapies, adjunct strategies and new targeted therapies. Take home message: Regional chemotherapy is a viable, evolving treatment for patients with in-transit melanoma and a springboard for ongoing research aimed at improving therapies for malignant melanoma.

Original languageEnglish (US)
Pages (from-to)79-93
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Volume11
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

Melanoma
Drug Therapy
Extremities
Perfusion
Complementary Therapies
Therapeutics
Neoplasm Metastasis
Melphalan
Pharmacokinetics
Lymph Nodes
Skin
Research

Keywords

  • Isolated limb infusion
  • Isolated limb perfusion
  • Melanoma
  • Regional therapy
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Pharmacotherapy of regional melanoma therapy. / Padsis, James; Turley, Ryan; Tyler, Douglas.

In: Expert Opinion on Pharmacotherapy, Vol. 11, No. 1, 01.2010, p. 79-93.

Research output: Contribution to journalArticle

Padsis, James ; Turley, Ryan ; Tyler, Douglas. / Pharmacotherapy of regional melanoma therapy. In: Expert Opinion on Pharmacotherapy. 2010 ; Vol. 11, No. 1. pp. 79-93.
@article{1670510ea7244163b52b7f5a20dfab01,
title = "Pharmacotherapy of regional melanoma therapy",
abstract = "Importance of the field: In-transit melanoma metastases develop within regional dermal and subdermal lymphatics before reaching the regional lymph nodes. The prognosis is poor and comparable to multiple nodal metastases. Isolated limb infusion (ILI) or perfusion (ILP) are effective treatments for unresectable, in-transit melanoma, with response rates reaching 95{\%}. Although ILI and ILP are more effective than systemic therapy, most patients will recur, thus highlighting the need for newer strategies to improve durable response rates. Areas covered in this review: We review historical and current literature from 1958 to 2009 regarding regional therapy for melanoma, with focus on the ILI and ILP techniques, pharmacokinetics and resistance mechanisms of melphalan. Alternative therapies, adjunct strategies and new targeted therapies aimed at improving response rates and long-term remission are also discussed. What the reader will gain: The reader will gain a comprehensive review on regional pharmacotherapy for melanoma, including alternative therapies, adjunct strategies and new targeted therapies. Take home message: Regional chemotherapy is a viable, evolving treatment for patients with in-transit melanoma and a springboard for ongoing research aimed at improving therapies for malignant melanoma.",
keywords = "Isolated limb infusion, Isolated limb perfusion, Melanoma, Regional therapy, Targeted therapy",
author = "James Padsis and Ryan Turley and Douglas Tyler",
year = "2010",
month = "1",
doi = "10.1517/14656560903428003",
language = "English (US)",
volume = "11",
pages = "79--93",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Pharmacotherapy of regional melanoma therapy

AU - Padsis, James

AU - Turley, Ryan

AU - Tyler, Douglas

PY - 2010/1

Y1 - 2010/1

N2 - Importance of the field: In-transit melanoma metastases develop within regional dermal and subdermal lymphatics before reaching the regional lymph nodes. The prognosis is poor and comparable to multiple nodal metastases. Isolated limb infusion (ILI) or perfusion (ILP) are effective treatments for unresectable, in-transit melanoma, with response rates reaching 95%. Although ILI and ILP are more effective than systemic therapy, most patients will recur, thus highlighting the need for newer strategies to improve durable response rates. Areas covered in this review: We review historical and current literature from 1958 to 2009 regarding regional therapy for melanoma, with focus on the ILI and ILP techniques, pharmacokinetics and resistance mechanisms of melphalan. Alternative therapies, adjunct strategies and new targeted therapies aimed at improving response rates and long-term remission are also discussed. What the reader will gain: The reader will gain a comprehensive review on regional pharmacotherapy for melanoma, including alternative therapies, adjunct strategies and new targeted therapies. Take home message: Regional chemotherapy is a viable, evolving treatment for patients with in-transit melanoma and a springboard for ongoing research aimed at improving therapies for malignant melanoma.

AB - Importance of the field: In-transit melanoma metastases develop within regional dermal and subdermal lymphatics before reaching the regional lymph nodes. The prognosis is poor and comparable to multiple nodal metastases. Isolated limb infusion (ILI) or perfusion (ILP) are effective treatments for unresectable, in-transit melanoma, with response rates reaching 95%. Although ILI and ILP are more effective than systemic therapy, most patients will recur, thus highlighting the need for newer strategies to improve durable response rates. Areas covered in this review: We review historical and current literature from 1958 to 2009 regarding regional therapy for melanoma, with focus on the ILI and ILP techniques, pharmacokinetics and resistance mechanisms of melphalan. Alternative therapies, adjunct strategies and new targeted therapies aimed at improving response rates and long-term remission are also discussed. What the reader will gain: The reader will gain a comprehensive review on regional pharmacotherapy for melanoma, including alternative therapies, adjunct strategies and new targeted therapies. Take home message: Regional chemotherapy is a viable, evolving treatment for patients with in-transit melanoma and a springboard for ongoing research aimed at improving therapies for malignant melanoma.

KW - Isolated limb infusion

KW - Isolated limb perfusion

KW - Melanoma

KW - Regional therapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=72849146433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72849146433&partnerID=8YFLogxK

U2 - 10.1517/14656560903428003

DO - 10.1517/14656560903428003

M3 - Article

C2 - 20001431

AN - SCOPUS:72849146433

VL - 11

SP - 79

EP - 93

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -